Key Takeaways
- • Moderna exemplifies venture capital's value capture mechanism: Despite operating at massive losses ($747 million in 2020), the company achieved a $12.2 billion profit in 2021 and $8.4 billion in 2022 following its mRNA vaccine commercialization, demonstrating how VC-backed biotech firms accumulate future social necessity during crises.
- • VC funding enabled rapid pandemic response: Moderna brought its first-ever product to market in late 2020 after receiving the COVID-19 virus genetic sequence only 42 days prior to FDA emergency use authorization, supported by a $1.5 billion U.S. government preorder, illustrating how venture capital mobilizes resources during global emergencies.
- • Cambridge research identifies structural tension in VC models: The peer-reviewed article, published open-access in *Finance and Society* through Cambridge University Press, explores how venture capital simultaneously pursues profit accumulation while positioning itself as solving urgent social crises—a "rapacious ambivalence" embedded in VC's foundational mechanisms.
- • First-product commercialization after decade of losses: Moderna's trajectory from the largest biotech IPO in history (pre-2018) through years of negative operating performance to blockbuster profitability reveals how VC structures enable long-term value positioning that traditional public market metrics would not support.
Summary
A Cambridge University Press-published research article by M. Howard examines venture capital as a mechanism for accumulating and capturing future social necessity, using Moderna's COVID-19 vaccine development as a central case study. The article, published open-access in *Finance and Society* (2024), explores what the author terms the "rapacious ambivalence" of venture capital investment—the paradox wherein VC firms pursue profit maximization while simultaneously positioning their investments as solutions to systemic crises.
Moderna's pandemic response illustrates this dynamic starkly. By March 11, 2020, when the WHO designated COVID-19 a pandemic, Moderna had already submitted its mRNA-1273 vaccine candidate for Phase 1 human trials at the National Institute for Health—having obtained the virus's genetic sequences merely 42 days earlier when the WHO made them public. This rapid mobilization, enabled by over a decade of venture backing despite cumulative operational losses, positioned Moderna as a critical actor in the global health emergency. The company had gone public in one of the largest biotech IPOs on record yet continued posting annual net operating losses reaching $747 million in 2020 alone.
The financial inflection point came following market authorization. Moderna received emergency use authorization from the FDA and secured a $1.5 billion preorder from the Trump administration in late 2020 for mRNA-1273—notably, the company's first product ever brought to market in its decade-long existence. This marked the transition from loss accumulation to extraordinary profitability: Moderna reported $12.2 billion in net profit in 2021, followed by $8.4 billion in 2022. Howard's research analyzes this trajectory as emblematic of how venture capital structures enable long-term value positioning during crises, accumulating what might be termed "future social necessity" as proprietary assets.
The article contributes to emerging scholarly discourse on how venture capital, sustainable finance, and crisis response mechanisms interact within contemporary financial systems—positioning VC not merely as capital allocation but as a structural process of value capture tied to social urgency.
Moderna's pandemic response illustrates this dynamic starkly. By March 11, 2020, when the WHO designated COVID-19 a pandemic, Moderna had already submitted its mRNA-1273 vaccine candidate for Phase 1 human trials at the National Institute for Health—having obtained the virus's genetic sequences merely 42 days earlier when the WHO made them public. This rapid mobilization, enabled by over a decade of venture backing despite cumulative operational losses, positioned Moderna as a critical actor in the global health emergency. The company had gone public in one of the largest biotech IPOs on record yet continued posting annual net operating losses reaching $747 million in 2020 alone.
The financial inflection point came following market authorization. Moderna received emergency use authorization from the FDA and secured a $1.5 billion preorder from the Trump administration in late 2020 for mRNA-1273—notably, the company's first product ever brought to market in its decade-long existence. This marked the transition from loss accumulation to extraordinary profitability: Moderna reported $12.2 billion in net profit in 2021, followed by $8.4 billion in 2022. Howard's research analyzes this trajectory as emblematic of how venture capital structures enable long-term value positioning during crises, accumulating what might be termed "future social necessity" as proprietary assets.
The article contributes to emerging scholarly discourse on how venture capital, sustainable finance, and crisis response mechanisms interact within contemporary financial systems—positioning VC not merely as capital allocation but as a structural process of value capture tied to social urgency.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.